Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.

[1]  T. Yoshikawa,et al.  Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer , 2015, Annals of Surgical Oncology.

[2]  A. Ulrich,et al.  Prognostic Relevance of Palliative Primary Tumor Removal in 37,793 Metastatic Colorectal Cancer Patients: A Population-Based, Propensity Score-Adjusted Trend Analysis. , 2015, Annals of surgery.

[3]  A. Ohtsu,et al.  Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. , 2014, The oncologist.

[4]  L. Helyer,et al.  A systematic review of surgery for non-curative gastric cancer , 2012, Gastric Cancer.

[5]  M. Koch,et al.  Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555) , 2012, BMC Cancer.

[6]  M. Shah,et al.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Tae Won Kim,et al.  A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models , 2011, Cancer Chemotherapy and Pharmacology.

[8]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[9]  S. Steinberg,et al.  The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone , 2009, Trials.

[10]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.

[11]  Y. Ohashi,et al.  Meta-analyses of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[13]  J. Heo,et al.  Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[15]  H. Putter,et al.  Value of palliative resection in gastric cancer , 2002, The British journal of surgery.

[16]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[17]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[18]  C. V. D. van de Velde,et al.  Tumor load and surgical palliation in gastric cancer. , 2001, Hepato-gastroenterology.

[19]  Y. Kakugawa,et al.  Therapeutic significance of palliative operations for gastric cancer for survival and quality of life , 1998, Journal of surgical oncology.

[20]  A. Kakita,et al.  Gastric cancer with metastases to the distant peritoneum: a 20-year surgical experience. , 1998, Hepato-gastroenterology.

[21]  Y. Maehara,et al.  Surgical treatment for advanced gastric cancer. , 1996, Hepato-gastroenterology.

[22]  D L DeMets,et al.  Interim analysis: the alpha spending function approach. , 1994, Statistics in medicine.

[23]  D J Spiegelhalter,et al.  Applying Bayesian ideas in drug development and clinical trials. , 1993, Statistics in medicine.

[24]  A. Viste,et al.  The survival benefit of resection in patients with advanced stomach cancer: The norwegian multicenter experience , 1989, World Journal of Surgery.

[25]  R. Audisio,et al.  Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. , 1987, Surgery, gynecology & obstetrics.

[26]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[27]  S. Meijer,et al.  Palliative resection in gastric cancer , 1983, Journal of surgical oncology.

[28]  O. Kimura,et al.  Therapeutic significance of noncurative gastrectomy for gastric cancer with liver metastasis. , 1980, American journal of surgery.

[29]  E. Chiorean.  Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study , 2012 .

[30]  D. Cunningham,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2010, The New England journal of medicine.